Evrys Bio
Evrys Bio is a pioneering biotechnology company focused on developing broad-spectrum antiviral therapies. Founded on breakthrough discoveries from Princeton University, the company aims to transform the treatment of viral infections by targeting human proteins known as sirtuins. This innovative approach enhances the body's natural immunity, offering a high barrier to drug resistance and addressing multiple viruses simultaneously. Evrys Bio's vision is to provide first-in-class antivirals that are safe and effective against a wide range of infectious diseases, ultimately transforming medical practice by focusing on disease conditions rather than individual viruses.
Industries
Nr. of Employees
small (1-50)
Evrys Bio is currently seeking investment
Evrys Bio is seeking a series-a investment in the range of 5m-20m
Patents
Products
Pan‑respiratory broad‑spectrum antiviral program
Preclinical program developing sirtuin‑targeted small molecules active against multiple respiratory viruses including coronaviruses, RSV, adenoviruses and influenza A/B (including drug‑resistant strains).
Antiviral program for opportunistic infections in immunocompromised patients
Small‑molecule sirtuin modulators optimized to prevent or treat opportunistic viral infections in immunosuppressed patients (e.g., cytomegalovirus and other herpes‑ and polyomaviruses).
Medical countermeasure program for emerging/pandemic viruses
Host‑targeted broad‑spectrum antivirals intended as rapid‑response therapeutics and stockpiled countermeasures against emerging viral threats.
Liver infections antiviral program (hepatitis‑focused)
Sirtuin‑targeted small‑molecule program aimed at major causes of viral hepatitis with preclinical data indicating effects on hepatitis B virus replication and cccDNA establishment.
Pan‑respiratory broad‑spectrum antiviral program
Preclinical program developing sirtuin‑targeted small molecules active against multiple respiratory viruses including coronaviruses, RSV, adenoviruses and influenza A/B (including drug‑resistant strains).
Antiviral program for opportunistic infections in immunocompromised patients
Small‑molecule sirtuin modulators optimized to prevent or treat opportunistic viral infections in immunosuppressed patients (e.g., cytomegalovirus and other herpes‑ and polyomaviruses).
Medical countermeasure program for emerging/pandemic viruses
Host‑targeted broad‑spectrum antivirals intended as rapid‑response therapeutics and stockpiled countermeasures against emerging viral threats.
Liver infections antiviral program (hepatitis‑focused)
Sirtuin‑targeted small‑molecule program aimed at major causes of viral hepatitis with preclinical data indicating effects on hepatitis B virus replication and cccDNA establishment.
Expertise Areas
- Host‑targeted antiviral drug discovery
- Medicinal chemistry and lead optimization
- Structure‑based drug design and computational chemistry
- Preclinical virology and in vivo efficacy evaluation
Key Technologies
- Sirtuin‑targeted small‑molecule modulation
- Computer‑aided drug design
- X‑ray crystallography and structural analysis
- Biochemical enzymatic assays
Key People
Lillian W. Chiang, PhD, MBA
President & CEO
Thomas E. Shenk, PhD
Founder and Board Director
Stacy W. Remiszewski, PhD
Vice President - Research
Robert Drakas
Chief Strategy Officer
Jens Erik Knudsen, BS, MBA
Chief Financial Officer
F. Aaron Dubberley, Esq.
Head of Intellectual Properties
Lillian W. Chiang, PhD, MBA
President & CEO
Thomas E. Shenk, PhD
Founder and Board Director
Stacy W. Remiszewski, PhD
Vice President - Research
Robert Drakas
Chief Strategy Officer
Jens Erik Knudsen, BS, MBA
Chief Financial Officer
F. Aaron Dubberley, Esq.
Head of Intellectual Properties
Investors
Defense Threat Reduction Agency (DTRA)
Series A - Evrys Bio
Mid Atlantic Bio Angels
Seed Round - Evrys Bio
Seed Round - Evrys Bio
Defense Threat Reduction Agency (DTRA)
Series A - Evrys Bio
Mid Atlantic Bio Angels
Seed Round - Evrys Bio
Seed Round - Evrys Bio
News & Updates
Evrys Bio will participate in the CBDS&T meeting in December 2024 in Ft. Lauderdale.
Lillian Chiang, CEO of Evrys Bio, presented at the BioCentury’s East-West Biopharma Summit in Boston.
Evrys Bio received $34 million from the Department of Defense to develop a single drug effective against multiple lethal viruses.
An article discussing the broad-spectrum anti-infective activity of drugs targeting Sirtuin 2.
Research on an allosteric inhibitor of Sirtuin 2 that blocks hepatitis B virus DNA establishment and transcriptional activity.
Evrys Bio was awarded a Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease for developing a single antiviral to treat multiple opportunistic infections.
Evrys Bio will participate in the CBDS&T meeting in December 2024 in Ft. Lauderdale.
Lillian Chiang, CEO of Evrys Bio, presented at the BioCentury’s East-West Biopharma Summit in Boston.
Evrys Bio received $34 million from the Department of Defense to develop a single drug effective against multiple lethal viruses.
An article discussing the broad-spectrum anti-infective activity of drugs targeting Sirtuin 2.
Research on an allosteric inhibitor of Sirtuin 2 that blocks hepatitis B virus DNA establishment and transcriptional activity.
Evrys Bio was awarded a Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease for developing a single antiviral to treat multiple opportunistic infections.